Breaking News

Lantern Pharma Reacquires Irofulven from Allarity Therapeutics

Based on early Phase II results, Lantern to advance development in bladder and prostate cancer with a key mutation in the ERCC2/3 genes.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allarity Therapeutics A/S and Lantern Pharma Inc. have entered an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full responsibility for future clinical development and commercialization.   Irofulven is a small molecule that causes bulky single strand DNA adducts that cause DNA damage in cancer cells, which can only be repaired by the transcription coupled nucleotide excision repair (TC-NER) pathway. This DNA modification stalls RNA polyme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters